Weight stigma clashes with GLP-1 drug marketing and body-positivity
Experts warn that aggressive advertising for GLP-1 weight-loss drugs fuels body-shaming and harms mental health, even as the medicines have legitimate medical uses.
The surge in GLP-1 drug promotion has sparked concern among health professionals who see the messaging as a new front in weight-bias culture. Virgie Tovar, who lives in San Francisco and runs the GLP-1 Truth Serum podcast, says a recent advertisement upset her enough to cancel personal plans, highlighting the emotional toll of such ads on vulnerable individuals. Emma Beckett, a nutrition researcher from Sydney, used Ozempic to alleviate pain but stopped when the drug limited her diet to bland foods, yet she still supports its judicious use without stigma.
Gemma Sharp, a professor at the University of Adelaide, points out that weight stigma existed long before these drugs and that the current hype mirrors past diet-culture tactics, urging people to focus on body function rather than appearance. All three agree that while GLP-1s can be medically appropriate, the aggressive marketing strategies risk worsening mental-health outcomes for those already struggling with body image.
Why it matters
The piece highlights how drug marketing can intensify weight bias, affecting mental health and body-image across society.
In this story